Swiss life science startups headed for San Diego

41 Swiss life science companies, including 27 startups, will participate in the upcoming BIO International 2024 conference in San Diego from 3 to 6 June, joining 5,000 attending companies and 15’000 visitors from across the world. The Swiss delegation will presenting their innovative solutions in the fields of drug discovery, clinical trial management and pharmaceutical consulting services at the Swiss pavilion. 

The BIO International Convention 2024, taking place in San Diego from 3 to 6 June, is the largest global biotechnology event with over 20,000 industry leaders from around the world attending. The target group includes representatives from publicly traded pharmaceutical companies, biotech startups, academia, non-profit organisations or government, as well as individual researchers, business developers or investors, who can benefit from one week of intensive networking to discover new opportunities and promising partnerships. Last year more than 20’000 visitors attended, out of which 45% were international attendees. This year around 15’000 visitors will be expected, including 5’000 exhibiting companies. 

Switzerland will once again participate to exhibit why the country remains at the top of the Global Innovation Index. The Swiss delegation of 41 companies will present in the Swiss Biotech Pavilion, organised by Switzerland Global Enterprise, Presence Switzerland, the Swiss Biotech Association, Innosuisse, Swissnex and the Swiss Business Hub USA. Among them are 27 Swiss startups, 9 of which are supported by Innosuisse. 

The participating life science startups include: ag (Buchrain): Specializes in leveraging artificial intelligence for advanced data analysis in biomedical research.

Bacthera SA (Basel): Focuses on the manufacture of live biotherapeutic products for pharmaceutical clients.

BioVersys AG (Basel): Engages in the research and development of drugs that address antimicrobial resistance.

DiNABIOS a DiNAQOR Group Company (Zurich): Specializes in innovative therapies for patients with genetic heart diseases.

InSphero AG (Schlieren): Develops and produces 3D microtissues for drug discovery and toxicity testing.

Molecular Partners AG (Schlieren): Develops a new class of custom-built protein therapeutics known as DARPin® molecules.

Novigenix (Lausanne): Focuses on developing and commercializing blood tests for early cancer detection and precision medicine.

Obaris AG (Zurich): Specializes in the development and commercialization of orthopedic and surgical implants.

PDC Therapeutics(Lausanne): Focuses on developing precision drugs for the treatment of severe and rare diseases.

Superlab Suisse AG (Zurich): Provides high-tech laboratory services and research facilities for life sciences companies.

 Alpha Onco (Monthey): Engages in the development of innovative oncology treatments.

Ceidos SA (Sion): Specializes in virtual reality solutions, primarily for therapeutic and rehabilitation applications.

Curio Biotech SA (Visp): Focuses on developing novel treatments based on cell secretome for regenerative medicine.

Excellgene (Monthey): Produces biopharmaceuticals using advanced cell line engineering and protein production technologies.

Novochizol SA (Monthey): Develops chitosan-based formulations to enhance the delivery of biopharmaceuticals.

Orio Therapeutics (Monthey): Specializes in developing therapies for respiratory diseases.

Stämm Biotech (Monthey): Works on bioprocesses that utilize human stem cells for regenerative medicine.

ten23 health(Basel): Offers services in drug development and manufacturing, with a focus on sustainable practices.

Startups supported by Innosuisse are:  

Amphilix (Basel): Focuses on innovative technologies for biopharmaceutical development and production.

Cellestia Biotech (Basel): Specializes in developing targeted therapies for cancer and other severe diseases based on modulating gene expression.

cellvie (Zurich): Dedicated to advancing mitochondrial transplantation therapy to treat acute and chronic degenerative diseases.

FluoSpera(Geneva): Provides high-throughput screening services using innovative fluorescence-based technologies.

Nagi Bioscience (Lausanne): Develops the first Organism-on-Chip technology for automated and ethical testing of drugs and chemicals.

REM Analytics (Lausanne): Specializes in microbiome analytics and solutions for healthcare and agricultural applications.

Scailyte (Basel): Uses single-cell technologies and AI-driven data analysis to discover biomarkers and advance precision medicine.

Synendos Therapeutics (Basel): Focuses on the development of breakthrough therapies for the treatment of central nervous system disorders.

Vandria (Lausanne): Offers digital solutions to enhance the efficiency and effectiveness of healthcare and medical management.

Switzerland Global Enterprise with its partner Swissnex in Boston and New York will be hosting a Swiss reception on Tuesday June 4th from 5pm to 6:30pm at the Swiss Pavilion, booth #2111. 

(Press release / SR)